M&As this week: Sygnis, Incyte, Aptuit

12 May 2016 (Last Updated May 12th, 2016 18:30)

Biotechnology company Sygnis AG plans to acquire proteomics company Expedeon to expand its product portfolio and develop sales in the US and European markets.

Biotechnology company Sygnis AG plans to acquire proteomics company Expedeon to expand its product portfolio and develop sales in the US and European markets.

The company has announced its plans to raise funds amounting to $23.4m by issuing rights offerings of up to 20,538,089 shares, and has further announced an offering of the unsubscribed new shares to the Expedeon shareholders.

Incyte has entered an agreement with ARIAD Pharmaceuticals to acquire all the shares and European operations of ARAID.

The agreement allows Incyte to develop its European medical and commercial market and ARIAD Pharmaceutical to strengthen its financial position and commercialise Iclusig in the US.

Iclusig is indicated for the treatment of T315I-positive chronic myeloid leukemia (CML) or T315I-positive, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients.

Aptuit plans to expand its formulation development capabilities in pre-formulation, formulation prototyping and formulation development service, through the acquisition of Kuepcept LTD.

The former is a pharmaceutical services company and the latter is a UK-based, drug development service provider.